Antiplatelet agents for the secondary prevention of ischaemic stroke in patients with or without renal dysfunction.

I-K WangT-H YenY-C GuoY SunL-M LienW-L ChangP-L ChenY-C YangFung-Chang SungC Y Hsu

Published in: European journal of neurology (2019)

There was no difference in the risks of recurrent stroke and 1-year mortality amongst ischaemic stroke patients with or without renal dysfunction receiving antiplatelet agents with aspirin, clopidogrel or dual agents with a combination of aspirin and clopidogrel, regardless of their renal dysfunction status.

Keyphrases

antiplatelet therapy
acute coronary syndrome
cardiovascular events
low dose
oxidative stress
percutaneous coronary intervention
atrial fibrillation
risk assessment
human health
subarachnoid hemorrhage